Better Science, Better Health
“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.
“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.
“Better Science, Better Health” has three core areas of focus:
- Harnessing real world evidence for better decision-making and create better patient outcomes
- Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
- Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines
Latest Events
Webinar: Cancer care during a pandemic – what have we learned so far?
10 March, 18:00-18:30
It will probably take years before we can understand the impact of the Covid-19 pandemic on cancer patients. We know about decreasing diagnosis, interrupted treatment cycles, and other unintended effects of pandemic control measures. We don’t know, however, what exactly these changes mean for cancer patients and their survival rates.
Even though high-quality data is often lacking and there is significant heterogeneity in real world evidence connecting treatment delays with increased mortality, studies increasingly highlight delays in cancer treatment during the past months. More recently, there have also been attempts to standardize estimates of the effects of treatment delays on survival rates, offering important lessons for cancer care systems.
How can we quantify the impact of delays in cancer treatment on mortality? What do we know about the causal links between pandemic control measures and cancer care? How can patients, health care professionals, and policymakers help minimize delays in cancer treatment initiation?
Europe’s Beating Cancer Plan: Why we need it now
10 Feb, 2021, 08:30 – 09:00 CET
"Europe’s Beating Cancer Plan” sounds like something that should be around already. With the Europeans carrying 25% of the global population’s cancer burden, a coherent strategy tackling cancer incidence and mortality in Europe is only consequential. Or is it?
Cancer treatment remains a personal and often local matter, and different perspectives exist across Europe on access to cancer care, budgets, and spending. These are reflected in different public health systems and policies at the level of EU member states. Cancer control activities vary greatly within Europe as do the outcomes of cancer care.
Considering high European ambitions, persisting interests in member states, and local sensitivities: What can we expect from Europe’s Beating Cancer Plan? How can it become a success and more than just yet another document?
Webinar: What can Europe learn from Germany’s ‘National Decade Against Cancer’?
17th June 2020, 11.00-12.00 CET
While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?
Latest News
Belgium makes a U-turn on AstraZeneca jab in over-55s
Belgium is the latest European country to make a U-turn on the AstraZeneca vaccine, now recommending it for use in people over 55 years of age. The country's Superior Health Council said data from new, large-scale studies in the UK, which showed strong efficacy in older age groups "is reassuring at first sight," and deemed the jab safe and effective. Belgium was one of a handful of countries – including Germany, France and Italy – that limited the use of the AstraZeneca vaccine last month, despite the European Medicines Agency saying it was safe for anyone over the age of 18.
How Europe fell behind on vaccines
The European Union's vaccination effort came under fire just as it was beginning to deliver. Heralded for months as the flagship of European solidarity during the coronavirus pandemic, the European Commission’s strategy of joint vaccine procurement is now being accused by national leaders of being too bureaucratic, too limiting to its members, too slow.
EHFG: CAR-T: The evolution of a revolution?
Do CAR-T – Chimeric antigen receptor T-cell – therapies have the potential to revolutionise cancer care? These therapies are disrupting traditional concepts of immuno-oncology, manufacturing, delivery and value across Europe. However, for many, there remain a number of open questions that need to be addressed. This session highlighted the transformative potential of these therapies, and sceptical voices who will focus on the unknown variables and where current challenges lie.
Newsletter
Register now to receive all the latest news and events.
Latest Research
Our consultancy services
The Economic Pandemic: Aggressive Testing Is Vital to Controlling the Spread of COVID19 and Saving Europe’s Economy
8th April 2020
By Duane Schulthess, Gergana Koleva, Anja Schiel, Harry P. Bowen, and Luca Pani
For the last month, a debate has raged over which approach to managing the spread of COVID-19 is correct. One aspect of this debate is about the efficacy of widespread testing.
Videos
Visit our youtube channel to view all of our videos.